crizanlizumab
Jump to navigation
Jump to search
Indications
- prevention of sickle cell painful crises
* may be used in conjunction with hydroxyurea
Dosage
- 2.5-5.0 mg/kg every 4 weeks
Mechanism of action
- inhibits P-selectin
More general terms
References
- ↑ Ataga KI, Kutlar A, Kanter J et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med 2016 Dec 3; PMID: https://www.ncbi.nlm.nih.gov/pubmed/2795970